查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球胜肽藥物偶聯物市場2023-2030
市場調查報告書
商品編碼
1380413

全球胜肽藥物偶聯物市場2023-2030

Global Peptide Drug Conjugates Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 200 Pages | 商品交期: 2-3個工作天內

價格

預計全球胜肽藥物綴合物市場在預測期（2023-2030年）將以9.4%的CAGR成長。此市場歸因於癌症和代謝紊亂盛行率上升、新藥研發投資增加以及藥物開發技術進步等因素。根據 Globocan 2020，癌症病例數為 50,550,287 例。其中，全球新增病例總數19,292,789例。

細分市場前景

全球胜肽藥物偶聯物市場按類型和產品細分。根據類型，市場分為診斷和治療。根據產品，市場細分為 Melflufen、Lutetium、ANG1005、BT1718 和 CBX-12。在這一類型中，由於新興的標靶治療藥物具有增強的腫瘤滲透性和選擇性，因此預計治療細分市場將佔據相當大的市場佔有率。

預計 Melflufen 細分市場將在全球胜肽藥物偶聯物市場中佔據相當大的佔有率

其中，melflufen細分市場預計將在全球胜肽藥物偶聯物市場中佔據相當大的佔有率。此細分市場的成長歸因於人們對當前治療選擇的認知不斷提高、有利的報銷政策、Melflufen 的推出以及PDC 藥物在癌症治療中的快速應用。2021 年2 月，FDA 批准了第一個抗癌胜肽藥物結合物，美法崙氟芬醯胺或美氟芬，與地塞米松合併使用。基於2期HORIZON研究，該產品由瑞典生物技術公司Oncopeptides AB開發，獲得加速批准。患有難治性多發性骨髓瘤的成年患者，曾經接受過至少 4 種治療，且其疾病對至少 1 種蛋白酶體抑制劑、1 種免疫調節劑和 1 種 CD38 定向單株抗體難以治療。

區域展望

全球胜肽藥物偶聯物市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於開發和商業化新輸送系統的投資不斷增加，預計亞太地區將在全球市場中佔據顯著佔有率。

北美地區預計全球胜肽藥物偶聯物市場將以顯著的CAGR成長

在所有地區中，北美地區預計在預測期內將以相當大的CAGR成長。推動北美市場的主要因素是該地區癌症病例數量的增加，預計這肯定會影響未來幾年胜肽藥物綴合物市場的成長。根據美國癌症協會 (ACS) 的數據，2022 年，美國報告了約 1,918,030 例新癌症病例和 609,360 例癌症死亡病例。根據英國皇家學會出版組織報道，HPRP-A1-TAT是一種雜合胜肽，能破壞細胞膜，導致細胞質內容物快速滲漏，具有很強的抗癌活性。

市場參與者展望

服務全球胜肽藥物綴合物市場的主要公司包括： Angiochem Inc.、Bicycle Therapeutics, Inc.、Cybrexa Therapeutics Inc.、Novartis AG、Oncopeptides AB 等。市場參與者透過各種策略（包括併購、合作、合作、融資和新產品發布），為市場成長做出了巨大貢獻，以保持市場競爭力。例如，2023 年 9 月，總部位於日本神奈川的生物製藥上市公司 PeptiDream Inc. 與羅氏集團旗下美國基因泰克公司簽訂了一項新的多目標合作和許可協議，旨在發現和開發新型大環肽-放射性同位素藥物綴合物。

報告涵蓋：

  • 2022年市場價​​值資料分析及2030年預測。
  • 每個細分市場的年化市場收入（百萬美元）。
  • 主要地理區域的國家分析。
  • 全球胜肽藥物偶聯物市場的主要公司。根據現有資料，報告中還提供了與新產品發布相關的資訊以及相關新聞。
  • 透過確定未來強勁成長的關鍵細分市場來分析業務策略。
  • 市場進入和市場擴張策略分析。
  • 透過識別市場中「誰的立場」來制定競爭策略。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • Angiochem Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Bicycle Therapeutics, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Cybrexa Therapeutics Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Novartis AG
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Oncopeptides AB
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 全球胜肽藥物偶聯物市場（按類型）
    • 診斷
    • 治療性
  • 全球胜肽藥物偶聯物市場（按產品）
    • 梅爾氟芬
    • 錏
    • ANG1005
    • BT1718
    • CBX-12

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • AstraZeneca co.
  • Camurus AB
  • Chiasma, Inc.
  • CRINETICS PHARMACEUTICALS
  • Dauntless Pharmaceuticals
  • Ipsen Biopharmaceuticals, Inc.
  • Midatech Pharma PLC
  • PeptiDream Inc.
  • Peptron, Inc.
  • Pfizer Inc.,
  • Soricimed Biopharma
  • Teva Pharmaceuticals Inc.
  • Theratechnologies Inc.
  • Validus Pharmaceuticals LLC
  • WuXi AppTec Co., Ltd.
Product Code: OMR2027822

Title: Global Peptide Drug Conjugates Market Size, Share & Trends Analysis Report by Type (Diagnostic and Therapeutic), and by Product (Melflufen, Lutetium, ANG1005, BT1718 and CBX-12),Forecast Period (2023-2030).

The global peptide drug conjugates market is anticipated to grow at a CAGR of 9.4% during the Forecast Period (2023-2030). The market is attributed to factors including the increasing prevalence of cancer and metabolic disorders, rising investments in the R&D of novel drugs, and technological advancements in drug development. According to the Globocan 2020, number of cancer cases were 50,550,287. Of which, the total number of new cases 19,292,789 around the globe.

Segmental Outlook

The global peptide drug conjugates market is segmented on the type, and product. Based on the type, the market is sub-segmented into diagnostic and therapeutic. Based on the product, the market is sub-segmented into melflufen, lutetium, ANG1005, BT1718 and CBX-12. Among the type, the therapeutic sub-segment is anticipated to hold a considerable share of the market, owing to the emerging targeted therapeutic that present increased tumor penetration and selectivity.

The Melflufen Sub-Segment is Anticipated to Hold a Considerable Share of the Global Peptide Drug Conjugates Market

Among the product, the melflufen sub-segment is expected to hold a considerable share of the global Peptide Drug Conjugates market. The segmental growth is attributed to the owing to increasing awareness about current treatment options, favorable reimbursement policies, the launch of Melflufen and rapid uptake of PDC drugs in cancer therapy., In February 2021, the FDA approved the first anticancer peptide-drug conjugate, melphalan flufenamide, or melflufen, for use in combination with dexamethasone. Based on the phase 2 HORIZON research, the product, developed by the Swedish biotech company Oncopeptides AB, received accelerated approval. In adult patients with refractory multiple myeloma, who have received at least 4 prior lines of therapy and whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 CD38-directed monoclonal antibody.

Regional Outlook

The global peptide drug conjugates market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the rising investments to develop and commercialize new delivery systems.

The North America Region is Expected to Grow at a Significant CAGR in the Global Peptide Drug Conjugates Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. The major factors driving the North America market is the increasing number of cancer cases across the region is estimated to certainly impact the peptide drug conjugates market growth in upcoming years. According to the American Cancer Society (ACS), in 2022, around 1,918,030 new cancer cases and 609,360 cancer mortalities were reported in the US. As per the reports of Royal Society Publishing Organization, HPRP-A1-TAT, a hybrid peptide, can destroy the cell membrane to cause rapid leakage of cytoplasmic contents, and has a strong anti-cancer activity.

Market Players Outlook

The major companies serving the global peptide drug conjugates market include: Angiochem Inc., Bicycle Therapeutics, Inc., Cybrexa Therapeutics Inc., Novartis AG, Oncopeptides AB, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2023, PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company entered into a new multi-target collaboration and license agreement with US based Genentech, a member of the Roche Group, targeted on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global peptide drug conjugates market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Angiochem Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Bicycle Therapeutics, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Cybrexa Therapeutics Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Novartis AG
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Oncopeptides AB
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Peptide Drug Conjugates Market by Type
    • 4.1.1. Diagnostic
    • 4.1.2. Therapeutic
  • 4.2. Global Peptide Drug Conjugates Market by Product
    • 4.2.1. Melflufen
    • 4.2.2. Lutetium
    • 4.2.3. ANG1005
    • 4.2.4. BT1718
    • 4.2.5. CBX-12

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AstraZeneca co.
  • 6.2. Camurus AB
  • 6.3. Chiasma, Inc.
  • 6.4. CRINETICS PHARMACEUTICALS
  • 6.5. Dauntless Pharmaceuticals
  • 6.6. Ipsen Biopharmaceuticals, Inc.
  • 6.7. Midatech Pharma PLC
  • 6.8. PeptiDream Inc.
  • 6.9. Peptron, Inc.
  • 6.10. Pfizer Inc.,
  • 6.11. Soricimed Biopharma
  • 6.12. Teva Pharmaceuticals Inc.
  • 6.13. Theratechnologies Inc.
  • 6.14. Validus Pharmaceuticals LLC
  • 6.15. WuXi AppTec Co., Ltd.

LIST OF TABLES

  • 1. GLOBAL PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL DIAGNOSTIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL THERAPEUTIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 5. GLOBAL MELFLUFEN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL LUTETIUM PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL ANG1005 PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL BT1718 PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL CBX-12 PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. NORTH AMERICAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 12. NORTH AMERICAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 13. NORTH AMERICAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 14. EUROPEAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 15. EUROPEAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 16. EUROPEAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 17. ASIA-PACIFIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 18. ASIA-PACIFIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 19. ASIA-PACIFIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 20. REST OF THE WORLD PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 21. REST OF THE WORLD PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL PEPTIDE DRUG CONJUGATES MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL DIAGNOSTIC PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL THERAPEUTIC PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL PEPTIDE DRUG CONJUGATES MARKET SHARE BY PRODUCT, 2022 VS 2030 (%)
  • 5. GLOBAL MELFLUFEN PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL LUTETIUM PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL ANG1005 PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL BT1718 PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CBX-12 PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. US PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 12. CANADA PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 13. UK PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 14. FRANCE PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. GERMANY PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. ITALY PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. SPAIN PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. REST OF EUROPE PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. INDIA PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. CHINA PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. JAPAN PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SOUTH KOREA PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF ASIA-PACIFIC PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. REST OF THE WORLD PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)